GoodRx Holdings (GDRX) EBIT (2019 - 2026)

GoodRx Holdings has disclosed EBIT across 8 years of filings, most recently posting $23.6 million for Q2 2026.

• In Q2 2026, EBIT fell 11.85% year-over-year to $23.6 million; the TTM figure through Jun 2026 stood at $74.9 million (down 15.58% YoY), while the FY2025 annual figure was $87.5 million, up 32.87% from the prior year.
• EBIT came in at $23.6 million for Q2 2026 at GoodRx Holdings, up from $14.0 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $26.8 million in Q2 2025 to a low of -$38.3 million in Q3 2023.
• Average EBIT over 5 years is $9.2 million, with a median of $16.4 million recorded in 2024.
• The largest YoY upside for EBIT was 552.38% in 2023 against a maximum downside of 1152.85% in 2023.
• Over 5 years, EBIT stood at $1.7 million in 2022, then slumped by 1152.85% to -$18.3 million in 2023, then soared by 199.41% to $18.2 million in 2024, then increased by 24.77% to $22.7 million in 2025, then grew by 4.18% to $23.6 million in 2026.
• Per Business Quant data, the three most recent EBIT figures were $23.6 million in Q2 2026, $14.0 million in Q1 2026, and $22.7 million in Q4 2025.